ClinicalTrials.gg
CompletedNCT04577404Updated Jul 20, 2026Results posted

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

A Phase 3 interventional study of MT-1186 in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.

Enrollment
13th of 20
124 · median 136
Started
2020
with 2 others
Phase 3
8 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
3 of 21
Shionogi

Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2020, is one of 8 in phase 3, and was the 12th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, or all of them as a file.
02

Study summary

This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must provide signed and dated form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study.
  2. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.
  3. Subjects who successfully completed Study MT-1186-A01.

Exclusion criteria

Exclusion Criteria:

  1. Subjects of unwilling to use a highly effective method of from Visit 1 until 3 months after the last dose of study medication.
  2. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS at Visit
  3. Subjects who are not eligible to continue in the study, as judged by the Investigator.
  4. Subjects who are unable to take their medications orally or through a PEG/RIG tube.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    MT-1186

    Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period

    Drug: MT-1186

Interventions

  • DrugMT-1186

    Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.

    Also known as: Oral Edaravone

06

What researchers measure

Primary outcomes

  1. Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death

    AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized. - Severe TEAEs: TEAEs which was classified as severe for the severity were analyzed. The severity of TEAEs was classified according to the following criteria: Mild (The event is transient and easily tolerated by the subject.), Moderate: The event causes discomfort and interferes with the subject's general condition.), and Severe (The event causes considerable interference with the subject's general condition and may be incapacitating.) - TESAEs, which is Serious TEAEs, is the TEAEs when the patients outcome is death, life-threatening, hospitalization, or disability or permanent damage.

    Time frame: up to 96 Weeks

  2. Number of Subjects of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

    AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized.

    Time frame: up to 96 Weeks

Other outcomes

  1. Change From Baseline of ALS Functional Rating Scale-Revised (ALSFRS-R) at Week 96

    ALS Functional Rating Scale- Revised (ALSFRS-R). The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.

    Time frame: Baseline to Week 96

  2. Number of Events of Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation

    Time frame: up to 96 Weeks

07

Results

Posted Aug 28, 2024

Participant flow

Participant flow — Overall Study
MilestoneMT-1186
Started124
Completed49
Not completed75
Withdrew: Adverse event31
Withdrew: Death1
Withdrew: Lack of efficacy3
Withdrew: Physician decision7
Withdrew: Withdrawal by subject21
Withdrew: Switched to commercial oral edaravon etc.12

Outcome measures

PrimaryNumber of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death

AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized. - Severe TEAEs: TEAEs which was classified as severe for the severity were analyzed. The severity of TEAEs was classified according to the following criteria: Mild (The event is transient and easily tolerated by the subject.), Moderate: The event causes discomfort and interferes with the subject's general condition.), and Severe (The event causes considerable interference with the subject's general condition and may be incapacitating.) - TESAEs, which is Serious TEAEs, is the TEAEs when the patients outcome is death, life-threatening, hospitalization, or disability or permanent damage.

Time frame:
up to 96 Weeks
Reported as:
Number · events
Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death
eventsMT-1186
Number of TEAEs616
Number of ADRs17
Number of severe TEAEs60
Number of TESAEs75
Number of TEAEs leading to discontinuation35
Number of TEAEs leading to death19
PrimaryNumber of Subjects of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized.

Time frame:
up to 96 Weeks
Reported as:
Count of participants · Participants
Number of Subjects of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
ParticipantsMT-1186
Number of TEAEs113
Number of ADRs12
Number of severe TEAEs44
Number of TESEAs52
Number of TEAEs leading to discontinuation28
Number of TEAEs leading to death19
Other pre-specifiedChange From Baseline of ALS Functional Rating Scale-Revised (ALSFRS-R) at Week 96

ALS Functional Rating Scale- Revised (ALSFRS-R). The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.

Time frame:
Baseline to Week 96

Results for this outcome have not been posted.

Other pre-specifiedNumber of Events of Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation
Time frame:
up to 96 Weeks

Results for this outcome have not been posted.

Adverse events

Collected over up to 96 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-118619/124 (15.3%)52/124 (41.9%)70/124 (56.5%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventMT-1186
Respiratory failureRespiratory, thoracic and mediastinal disorders13/124
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders9/124
DysphagiaGastrointestinal disorders7/124
Amyotrophic lateral sclerosisNervous system disorders6/124
DyspnoeaRespiratory, thoracic and mediastinal disorders4/124
PneumoniaInfections and infestations3/124
COVID-19Infections and infestations3/124
GastrostomySurgical and medical procedures2/124
Pneumonia staphylococcalInfections and infestations1/124
Urinary tract infectionInfections and infestations1/124
Most frequent other events
Showing 10 of 11
Most frequent other events
EventMT-1186
FallInjury, poisoning and procedural complications20/124
Muscular weaknessMusculoskeletal and connective tissue disorders18/124
ConstipationGastrointestinal disorders16/124
DyspnoeaRespiratory, thoracic and mediastinal disorders13/124
COVID-19Infections and infestations11/124
InsomniaPsychiatric disorders9/124
DysphagiaGastrointestinal disorders8/124
Urinary tract infectionInfections and infestations8/124
AnxietyPsychiatric disorders8/124
NauseaGastrointestinal disorders7/124

Baseline characteristics

Age, Continuous
Age, Continuous(years)MT-1186
Mean59.0 ± 10.1
Age, Customized
Age, Customized(Participants)MT-1186
Adults (18-64 years)84
From 65 to 84 years40
Sex: Female, Male
Sex: Female, Male(Participants)MT-1186
Female41
Male83
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MT-1186
Hispanic or Latino2
Not Hispanic or Latino118
Unknown or Not Reported4
08

Study locations

44 sites
  • St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center
    Phoenix, Arizona 85013, United States
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • UF Health Cancer Center
    Gainesville, Florida 32610-3633, United States
  • Emory University - School of Medicine
    Atlanta, Georgia 30317-2819, United States
  • Johns Hopkins University
    Baltimore, Maryland 21209, United States
  • Neurology Associates, P.C - Lincoln
    Lincoln, Nebraska 68506, United States
  • Wake Forest University Baptist Medical Center (WFUBMC) - The J. Paul Sticht Center on Aging and Rehabilitation
    Winston-Salem, North Carolina 27157, United States
  • Penn State Hershey Children's Hospital
    Hershey, Pennsylvania 17025, United States
  • Alleghany General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Texas Neurology, PA
    Dallas, Texas 75214, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Heritage Medical Research Clinic - University Of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM)
    Edmonton, Alberta T6G 2B7, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • CHU-Nice - Hopital Pasteur 2
    Nice, Cedex 1 06001, France
  • Centre Hospitalier Esquirol
    Limoges, Marcland 87025, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux
    Bordeaux, 33400, France
  • Hopital Pierre Wertheimer - Hopital Neurologique
    Paris, 75013, France
  • Deutsche Klinik fuer Diagnostik
    Wiesbaden, Hesse 65191, Germany
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)
    Milan, Lombardy 20132, Italy
  • Universita degli Studi di Torino - Centro Regionale Esperto Per La Sclerosi Laterale Amiotrofica (CRESLA)
    Turin, Piedmont 10126, Italy
  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca Granda - Centro Clinico Nemo (Neuro Muscular Omnicentre)
    Milan, 20162, Italy
  • Aichi Medical University Hospital
    Nagakute-shi, Aichi-ken 480-1195, Japan
  • National Hospital Organization Chibahigashi National Hospital
    Chiba, Chiba 260-8712, Japan
  • Murakami Karindoh Hospital
    Fukuoka, Fukuoka 819-8585, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • National Hospital Organization Hokkaido Medical Center
    Sapporo, Hokkaido 063-0005, Japan
  • National Hospital Organization Iou National Hospital
    Kanazawa, Ishikawa-ken 920-0192, Japan
  • Kagawa University Hospital
    Kita-gun, Kagawa-ken 761-0793, Japan
  • Kitasato University Hospital
    Sagamihara, Kanagawa 252-0375, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • National Hospital Organization Kumamoto Saishun Medical Center
    Koshi-shi, Kumamoto 861-1196, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Niigata University Medical And Dental Hospital
    Niigata, Niigata 951-8520, Japan
  • Kansai Electric Power Hospital Recruiting
    Fukushima-ku, Osaka-shi, Osaka 553-0003, Japan
  • National Hospital Organization Toneyama Medical Center
    Toyonaka-shi, Osaka 560-8552, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga 520-2192, Japan
  • National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, Shizuoka 420-8688, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Tokyo Metropolitan Neurological Hospital
    Fuchū, Tokyo 183-0042, Japan
  • Toho University Omori Medical Center
    Ōta-ku, Tokyo 143-8541, Japan
09

References and documents

Publications

  • Genge A, Pattee GL, Sobue G, Aoki M, Yoshino H, Couratier P, Lunetta C, Petri S, Selness D, Todorovic V, Sasson N, Hirai M, Takahashi F, Salah A, Apple S, Wamil A, Kalin A, Jackson CE. Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment. Muscle Nerve. 2025 Sep;72(3):450-454. doi: 10.1002/mus.28451. Epub 2025 Jun 9. PubMed 40485494 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2023, 33 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 6, 2020
StartActual
Oct 29, 2020
Primary completionActual
Aug 9, 2023
CompletionActual
Aug 9, 2023
Results first posted
Aug 28, 2024
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04577404
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Oct 6, 2020
Start date
Oct 29, 2020
Primary completion
Aug 9, 2023
Completion
Aug 9, 2023
Results posted
Aug 28, 2024
Last update
Jul 20, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion